75 results about "Therapy efficacy" patented technology

The present invention relates to a pharmaceutical composition comprising a weak acid drug, with the use of a bicarbonate salt to achieve a high incorporation of the drug into the liposome and a better therapeutic efficacy. Also disclosed is a method for treating a respiratory disease using the pharmaceutical composition disclosed herein.

The present invention provides improved and / or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody and / or anti-PD-L1 antibody and / or VEGF inhibitor, or wherein the NSCLC has a predetermined tumor proportion score (TPS).

The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.

This present disclosure relates to systems, methods, and compositions useful for profiling T cell receptor (TCR) and B cell receptor (BCR) repertoire using next-generation sequencing (NGS) methods. The present disclosure also relates to systems and methods for diagnosing, treating, or predicting infection, disease, medical conditions, therapeutic outcome, or therapeutic efficacy based on the TCR / BCR profile data from a subject in need thereof.

The present invention is based on a correlation found for the presence of the biomarker protein Cytotoxic T-lymphocyte protein 4, also known as CD152 or CTLA-4, on or in EVs, to their immunomodulatory efficacy. Hence, the invention provides a method for assessing the therapeutic efficacy of an EV or an EV-preparation by detecting the biomarker CTLA-4 in such EVs or EV-preparations. Furthermore, the invention provides a method for assessing the therapeutic efficacy of an EV or an EV-preparation by detecting at least one biomarker selected from the group of CTLA-4, PD1, PD-L1 and PD-L2 in the EV or EV-preparation. The method of the invention allows for an evaluation of the immunomodulatory efficacy of said EV preparations without the need of performing laborious functional in vivo or in vitro assays including mixed lymphocyte reaction assays. In three additional aspects of the invention, alternative methods for producing therapeutically active EVs or EV-preparations are provided. Further provided are therapeutically active EVs or EV preparations produced by the methods of the invention and their use in medicine, for example in the manufacturing of immunomodulatory medicaments.

The present application relates to cytokine-based bioactivatable drugs and methods of use thereof. The present invention provides a bioactivatable drug construct platform based on cytokines, aimed at reducing systemic toxicity, enabling proteins and cytokines, such as IL-15 and IL-2, to have a broader therapeutic use in the treatment of cancer, autoimmune diseases, inflammatory diseases, viral infections, transplantation and other disorders. The invention relates to a bioactivator comprising a tissue or disease site targeting portion D1 domain, a bioactivatable portion D2 domain and a shielding portion D3 domain. The active moiety of VitoKine remains inert until it is locally activated by an upregulated protease in diseased tissue, which limits binding of the active moiety to receptors or targets in the periphery or on the cell surface of non-diseased cells and tissues, prevents pathway over-activation and reduces undesirable "extracorporeal" "in-target" toxicity. Prior to protease activation, the inertness of the VitoKine active moiety significantly reduces potential antigen or target silencing, extends in vivo half-life and improves biodistribution, bioavailability and therapeutic efficacy.

Pharmaceutical compositions comprising anti-CEACAM1mAb and their use in the inhibition of NET-mediated activity and in the prevention and treatment of pathologies associated with these activities are provided, and are exemplified by mAb CM24 that also exhibit effective inhibition of cancer cell migration and NET-induced platelet aggregation. Prognostic methods based on NET-biomarkers for use in patient selection and monitoring of therapeutic efficacy are also presented.

The inventors have prepared a novel anti-Cath-D antibody (F1M1) that can reduce tumor growth in a Cath-D secreting basal-like TNBC cell line with strong immune infiltration, without significant toxicity. The F1M1 antibody prevents recruitment of immunosuppressive M2 polarized tumor-associated macrophages (TAMs) and induces activation of natural killer cells in the tumor, and the F1M1 also enhances activation of antitumor M1 polarized TAM, recruitment and maturation of conventional cDC1 dendritic cells in the tumor to promote antigen presentation and reduce depletion marker expression of CD4 + and CD8 + T cells in the tumor and drainage lymph nodes. It is worthy of noting that the affinity of the antibody F1M1 to Cath-D is better than that of the antibody F1 prepared by the inventor in advance. The inventors also have prepared a novel Fc-optimized F1M1-Fc + human antibody which can promote ADCC induction of cancer cells and CAF, improve anti-tumor efficacy, and trigger recruitment, activation and cytotoxic activity of NK cells in tumors. The F1M1-Fc + F1M1-Fc + can inhibit the growth of MDA-MB-231 and SUM159 TNBC cell xenografts and two TNBC-PDX (one of the TNBC-PDX is resistant to neoadjuvant chemotherapy), and has no obvious toxicity. In addition, the F1M1-Fc < + > improves the treatment effect of the paclitaxel and enzalutamide combined medicine. Thus, the present invention relates to anti-cathepsin-D antibodies and their use in the treatment of cancer, in particular triple negative breast cancer.

The lyophilized formulations comprise steepstercetin, including hydroxyurea methyl acyl fulvene and pharmaceutically acceptable salts thereof, in combination with a cyclodextrin. These formulations are designed to enhance the solubility, stability and therapeutic efficacy of steep steep cephalosporin, which has been illustrated due to its potent anti-cancer properties. Methods for producing these lyophilized formulations are provided, including a lyophilization process.

This invention belongs to the field of tumor detection and relates to a dynamic evaluation method for the efficacy of Bragg therapy driven by multi-cycle, multimodal peripheral blood data. The method includes the following steps: acquiring peripheral blood multimodal data from patients participating in Bragg therapy, and dividing the peripheral blood multimodal data into a training dataset and a validation dataset; constructing a Bragg therapy efficacy evaluation model using the training dataset, and validating the Bragg therapy efficacy evaluation model using the validation dataset; receiving peripheral blood multimodal data from patients participating in Bragg therapy, and calculating the evaluation results using the Bragg therapy efficacy evaluation model. This invention, by combining long short-term memory networks and graph neural networks, can effectively track the temporal changes of immune cell characteristics, thereby providing a more accurate basis for developing personalized treatment plans for Bragg therapy patients, improving treatment outcomes and survival rates.

tFUS delivery and tracking systems and methods assess target location accuracy and therapy efficacy by measuring the specific and predicted downstream effects in individualistic responses to tFUS waveforms. The downstream effects include physiological, stress, mood, movement, attention measurements, subjective reports, task-based performance, etc. The measurements are performed before, during, and between tFUS sessions intermixed with optional control periods or sessions. In an embodiment, when a target brain region does not offer any immediate readouts but is surrounded by regions that may, these latter regions can be used instead for triangulation or waveform optimization. Individual and group tracking methods help identify useful measurement modalities and the expected direction and magnitude of change in response to therapy. A method that enables individualized functional targeting in a non-clinical setting by optimizing cost and complexity is described.

Provided are multi-layer bioreactors for growing, maintaining, stimulating, monitoring and testing organoids and tissues derived from or representing hollow organs in organoid chambers. Also provided are uses of those bioreactors in modeling a disease process for monitoring disease progress and / or for assessing a biological effect, such as therapeutic efficacy and / or toxicity, e.g., organotoxicity. Also disclosed are bioreactors comprising organoid chambers that are useful as systems for measuring the volume, pressure, contractility, pump function, or electrophysiology of an organoid chamber as well as systems for controlling the pressure experienced by an organoid or tissue in an organoid chamber.

The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor—CAR) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof.

Methods for treating non-small cell lung cancer (NSCLC) include the administration of a combination of 2,2'-dithio-bis-ethane sulfonate, carboplatin, and pemetrexed. The methods are based on tumor mutational burden (TMB) assessment, with specific treatment regimens tailored to the mutational profile of the tumor. When a low tumor mutational burden is detected in a tumor sample, the combination therapy of 2,2'-dithio-bis-ethane sulfonate, carboplatin, and pemetrexed is administered, offering enhanced therapeutic efficacy.

A composition contains (i) rapamycin and / or a rapalog and (ii) a radiolabeled gastrin analogue. The composition can be used for the treatment and / or diagnosis of CCKB receptor positive cancer or tumors and leads to superior tumor uptake of radiolabeled gastrin analogue, resulting in improved delivery and therapeutic efficacy while cytotoxic side-effects are prevented and / or reduced.

Methods and compositions for PCR based means for generating gene-signature based risk scores for the prognosis of breast cancer recurrence and predicting therapy efficacy. The invention uses competitive amplification of 21 genes to encode the gene signature into the design of the oligonucleotides, making downstream amplification and subsequent analysis straight forward and suitable to be performed on-site. The 21 genes comprise the housekeeping module: ACTB, GAPDH, GUSB, RPLP0, and TFRC; the invasion module: CD68, CTSV, MMP11; the proliferation module: AURKA, BIRC5, CCNB1, MKI67, MYBL2; the HER2 module: ERBB2, and GRB7; and the Estrogen module; BAG1, BCL2, ESR1, GSTM1, PGR, and SCUBE2.

A system and method for distinguishing non-failing from failing cardiac fibroblasts (CFs) using advanced imaging techniques and machine learning (ML). The method involves staining CFs with fluorescent dyes to highlight key cellular components, such as nuclei and actin fibers. Images are analyzed to extract morphological features, which are then processed and normalized. A supervised ML system, trained on labeled CF data, classifies CFs based on phenotypic differences. The system enables accurate diagnosis of heart failure (HF), facilitates screening for therapeutic efficacy, and identifies antifibrotic agents by evaluating changes in CF phenotypes pre- and post-treatment.

Provided herein are biomarkers useful for identifying patients suitable for therapy comprising immune checkpoint inhibitors, and methods of using these biomarkers. In particular, the present disclosure provides techniques for treating and predicting cancer in a patient using biomarker expression levels in a biological sample obtained from the patient, as well as techniques for determining the likelihood that a patient will respond to therapy comprising an immune checkpoint inhibitor.

The present invention pertains to methods for survival prognosis, stratification, and assessment of disease progression or regression in Glioblastoma multiforme (GBM) patients. These methods are based on the detection and analysis of signature patterns of six specific metabolites in emotional tears samples. Additionally, the invention encompasses a preparation technique for emotional tears samples prior to liquid chromatography-mass spectrometry (LC-MS) analysis. This approach enables more accurate and reliable evaluation of GBM patient status and treatment efficacy through the examination of emotional tears metabolite profiles.

1. Name of the product in this design: Interactive graphical user interface for an oxygen chamber therapy effect evaluation system for electronic devices. 2. Intended use of this design: for use in an electronic device. 3. The key design feature of this product is its graphical user interface. 4. The image or photograph that best illustrates the design's key features: the front view. 5. Other orthographic views and perspective views are omitted. 6. Purpose of the graphical user interface: To display the main workflow and content of the hyperbaric oxygen therapy department. 7. Description of the changing states of the graphical user interface: The main view is the login interface; Figure 1 shows the interactive interface displayed after entering the correct username and password in the main view and clicking the "Login to System" button; Figure 2 shows the interactive interface displayed after clicking "Admission Treatment Management" in Figure 1; Figure 3 shows the interactive interface displayed after clicking "First Chamber" in Figure 2; Figure 4 shows the interactive interface displayed after clicking "Treatment Records" in Figure 3.

DEPCT64 This invention relates to 4 / 91IBV (Infectious Bronchitis Virus) which is coded for... Heterologous S (spike) protein or fragments thereof; furthermore, this invention also... This is related to the components that elicit an immune response, which include the aforementioned 4 / 91IBV. Process the code for heterologous S (spike) protein or fragments thereof. This invention also relates to a method for immunizing targets, which includes: Providing the target with an element that induces an immune response to this invention. Furthermore, this invention relates to methods for treating or preventing clinical symptoms caused by IBV. The necessary objectives involve a method of providing the target with the required quantity. The therapeutic efficacy of the immune response-inducing components according to this invention. -----------------------------------------------------------

The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor—CAR) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof.

A method for treating brain injury in a subject comprises administering a therapeutically effective amount of a PKM2 (pyruvate kinase M2) protein variant. The protein variant is delivered systemically and can reduce tissue damage after ischemic brain tissue reperfusion. The methods specifically involve the use of G415R mutants of PKM2 protein variants. The treatment is suitable for brain injury caused by hemorrhagic stroke and ischemic stroke. The PKM2 protein variants are ideally administered intravenously within one hour of reperfusion to maximize their therapeutic efficacy.

The invention provides methods and compositions for the simple PCR based means for generating gene-signature based risk scores for the prognosis of breast cancer recurrence and predicting therapy efficacy. The invention uses competitive amplification to encode the gene signature into the design of the oligonucleotides, 5 making downstream amplification and subsequent analysis straight forward and suitable to be performed on-site.

Described are methods for enhancing cancer immune surveillance and the efficacy of the treatment of melanoma or non-melanoma cancers such as pancreatic or colorectal cancers, particularly by controlling cancer cell-surface PD-L1 / L2 and the E3 ligase ITCH. Also described are methods of inhibiting an adaptive immune resistance response to anti-immune checkpoint protein therapy in a subject. As described herein, the efficacy of MAPK inhibitor therapy is increased by treatment with an activator of E3 ligase ITCH or a destabilizer of cell-surface PD-L1 / L2. As further demonstrated herein, the efficacy of anti-PD-1 / L1 therapy is also increased by treatment with an activator of E3 ligase ITCH or a destabilizer of cell-surface PD-L1 / L2.

Disclosed herein are methods and systems for detecting microorganisms in a sample and the use of such methods for selecting and monitoring therapies. The specificity of an indicator bacteriophage, such as a Staphylococcus specific bacteriophage, allows the detection of a particular microorganism, such as Staphylococcus, and the indicator signal can be amplified to optimize assay sensitivity.

Disclosed are methods for determining the pharmacodynamic activity of one or more compounds by measurement of focal accumulation of CIP2A. Further disclosed are methods of determining the effectiveness of a treatment with one or more compounds b measurement of focal accumulation of CIP2A. Compounds of the invention may be Polθ kinase inhibitors or PARP inhibitors.

The present invention relates to mouse antibodies that bind to angiopoietin-2 (Ang2), humanized anti-Ang2 antibodies derived therefrom, and the use thereof. The anti-Ang2 antibodies have a dual function of activating the Tie2 receptor together with neutralizing Ang2. The anti-Ang2 antibodies show the property of normalizing abnormal and pathological blood vessels, and thus exhibits therapeutic efficacy against various diseases and disorders associated with abnormal blood vessels. The present invention further provides an angiogenesis inhibitor and a composition for treatment of diseases associated with abnormal Ang2 expression and Tie2 dysregulation, which comprise the antibody as an active ingredient, and a composition for diagnosing diseases associated with Ang2 inhibition and Tie2 activation, which comprises the antibody.

This document describes a technique for evaluating therapy in patients with Restless Legs Syndrome (RLS). The technique can involve receiving a metric indicative of drug therapy administration and first sensor data that reflects leg movement or sleep quality during a desired relief period from RLS symptoms. A drug therapy efficacy indicator can be generated, such as based on the first sensor data and isolated from electrostimulation therapy effects. Such an indicator can assist a user or processes in evaluating the therapy's effectiveness for the patient. Such a technique can provide a systematic approach to assess the efficacy of drug therapy in managing RLS symptoms, enabling personalized treatment adjustments and improved patient outcomes.

Disclosed herein are UNC13A oligonucleotides having one or more spacer regions or having no spacer regions. In various embodiments, UNC13A oligonucleotides with spacer regions can reduce misspliced UNC13A transcripts and increase full-length UNC13A transcripts, resulting in therapeutic efficacy against neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or Alzheimer's disease (AD).